As a platform and window for China Pharmaceutical Group (the Group)’s "going out and bringing in" strategy, SINOPHARM FOREIGN TRADE has long been committed to the promotion on medical industrial investment and international business integration of the Group. Over the past three decades, the company has received a good return on many investment projects such as the establishment of Xi’an Janssen, Otsuka China, Shanghai bristol-myers squibb, Suzhou Capsugel, SINO-SWED Pharmaceutical Corp. Ltd and Qingdao Huazhong Pharmaceuticals Ltd. In recent years, the company mainly focuses on the implementation of the following investment projects, including the biomedical project in Vietnam and the setting up of Vietnam-China Pharmaceutical Co., Ltd (VCP), China National Pharmaceutical Group (Vietnam) Pharmaceutical Co., Ltd and Sinopharm-FTZ logistics Co., Ltd.

In the future, the company will set up a medium and long term strategic objective and continue targeting on the medical industrial investments. As a model role, the good practice of Vietnam projects will be extended to the area of ASEAN, Africa, South America and other developing markets. Meanwhile in Europe, America and other developed regions, the company shall actively explore for opportunities to expand international cooperation and make proper mergers and acquisitions of local pharmaceutical companies or businesses. By strengthen its brand effect and financial advantage, Sinopharm Foreign Trade is making great efforts in seeking for overseas strategic partners and is striving to build a strong operating platform for capitals. We believe that through the promotion of the international development of the Group, the company shall make great contributions for Chinese pharmaceutical industry.